Ekso Bionics Holdings Inc (EKSO) 株式分析

企業概要

Ekso Bionics Holdings, Inc. is an enterprise engaged in the design, development, distribution, and commercialization of advanced exoskeleton technologies across the Americas, Europe, the Middle East, Africa, the Asia Pacific, and international markets. The company operates within the Healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, where it provides specialized wearable robotic solutions such as the EksoNR and Ekso Indego Therapy devices. As of the latest reporting period, the enterprise maintains a market capitalization of $28.58M, generates annual revenue of $12.80M, and employs a workforce of 50 individuals. These financial metrics indicate that the company functions as a micro-cap entity with a relatively small operational footprint, suggesting a niche position in the broader medical technology landscape rather than a dominant market leader. The modest market capitalization coupled with limited revenue implies that the company is likely in an early growth or development stage, relying on its specific technological offerings to capture market share in a highly competitive and regulated environment.

財務健全性

The company reported total revenue of $12.80M over the trailing twelve months, while recording a net loss of $11,921,000 and an EBITDA of $-11,003,000. The substantial disparity between the positive revenue figure and the significant negative net income reveals a challenging cost structure where operating expenses, research and development costs, or sales commissions heavily outweigh gross profits. Free cash flow stands at $-4,496,125, which indicates that the company is consuming cash reserves to fund its operations and product development rather than generating liquidity for shareholder returns or debt repayment. Gross margin is reported at 53.5%, reflecting a relatively efficient production or sales model where the cost of goods sold is less than half of total revenue, yet this efficiency is insufficient to cover overhead. Operating margin sits at a negative 119.7% and profit margin is negative 91.4%, figures that demonstrate that operating expenses and taxes combined are drastically exceeding the gross profit generated, resulting in a severe loss on every dollar of revenue. The balance sheet shows cash holdings of $1.17M against total debt of $4.64M, with a debt-to-equity ratio of 51.45, indicating a leveraged position where liabilities exceed equity and the company relies on external financing to sustain its operations. Despite the leverage, the current ratio of 1.63 suggests that the company possesses sufficient current assets to cover its short-term liabilities, providing a baseline level of liquidity stability. Return on Equity is -107.6% and Return on Assets is -33.6%, metrics that reveal that management is currently unable to generate positive returns on the capital invested by shareholders or utilized in the asset base, highlighting significant operational inefficiencies or high capital burn rates typical of pre-profitability life sciences firms.

バリュエーション評価

The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is calculated at -42.21, implying that the market is pricing in expected future earnings growth that could turn the company profitable, though the current trajectory suggests continued losses. The price-to-book ratio stands at 3.16, indicating that the market values the company at a significant premium over its tangible book value, likely reflecting the intangible value of its intellectual property and proprietary exoskeleton technology. The price-to-sales ratio is 2.23 and the EV/EBITDA is -2.91, alternative metrics that suggest investors are willing to pay a multiple of sales despite the company's lack of profitability, a common valuation approach for high-growth potential biotech or medtech firms. The stock has traded within a 52-week range between a high of $13.50 and a low of $2.73, placing the current valuation somewhere within this historical volatility band where investors assess risk against the potential for future product adoption. The beta value is 0.78, which indicates that the stock price is less volatile than the broader market, suggesting lower systematic risk relative to large-cap equities but potentially compensating investors with higher long-term upside or downside depending on the success of its commercialization efforts.

Growth & Income

Revenue growth year-over-year is reported at -38.3%, while earnings growth is N/A due to the company's continued losses, indicating that the company is currently in a contraction phase regarding top-line sales rather than a period of expansion. The absence of positive earnings growth relative to revenue confirms that the business is struggling to maintain or increase sales volume, a critical concern for any company attempting to scale in the medical device sector. As a non-dividend payer, the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically reinvested into the business, although in this case, the company is burning cash to sustain operations. The overall growth and income profile presents a challenging picture characterized by declining revenue, significant negative earnings, and a lack of cash generation, requiring a successful pivot in sales strategy or product launch to alter the trajectory from contraction to expansion.